Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service CDMO, has acquired Velesco Pharmaceutical Services, Inc., a CDMO, specializing in liquid, semi-solid, and oral solid dose product development.
 
“Pace scientists and professionals provide expertise and support to clients throughout their drug development timeline,” said Eric Roman, CEO of Pace Analytical. “Adding Velesco to our portfolio is representative of our commitment to supporting customers across the drug delivery spectrum.”
 
The acquisition expands Pace’s range of support services; from binary solutions to complicated self-emulsifying drug delivery systems (SEDDS) and to tailor them to the client’s molecule, dose range, and drug delivery route. Velesco also extends Pace’s capabilities and clinical trial material manufacturing capacity including: developing pharmaceutical formulations for non-clinical toxicology studies, capabilities for small-scale, customized experiments that preserve limited compound supplies, complex drug product formulations, such as softgel capsule, suspension, and other non-sterile liquid pharmaceutical drug products.
 
Velesco co-founder and CEO David Barnes, Ph.D., will transition to Vice President, Scientific Affairs, and Velesco co-founder and COO Gerry Cox will assume the role of Vice President, Commercial Development at Pace.
 
“Dave Barnes and Gerry Cox have much to offer to the Pace team, and we are excited to have them continue on in key roles,” said Greg Kupp, President of Pace Life Sciences. “The reputation of the Velesco team, their strong history and flexible response to client demand, make this a great cultural fit while adding tremendous value to our clients.”